在因康恩腺瘤导致的原发性阿尔多斯特隆症中,左心室的重塑
G P Rossi1, A Sacchetto, E Pavan
1Department of Clinical and Experimental Medicine, University of Padua Medical School, Italy. gprossi@ipdunidx.unipd.it
Circulation
|March 18, 1997
概括
与基本高血压相比,阿尔多生成腺瘤 (APAs) 中的过量阿尔多会导致心脏壁较厚,腹填充受损. 这突显了阿尔多素对心脏结构和功能的直接影响.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 高血压研究 高血压研究
背景情况:
- 过高阿尔多斯特隆症在实验中与心肌间歇性纤维化有关.
- 产生阿尔多的腺瘤 (APA) 会导致过多的阿尔多和高血压.
研究的目的:
- 在APA患者中研究高血压和过量的阿尔多的心脏影响.
- 为了比较心脏结构和功能在APA患者与基本高血压 (EH) 患者.
主要方法:
- 多普勒回声心脏学以评估左心室 (LV) 的尺寸和填充.
- 24小时的门诊血压监测.
- 26名APA患者与26名EH患者的匹配比较.
主要成果:
- 与EH患者相比,APA患者表现出更厚的室间隔膜和后壁,以及更高的LV质量指数.
- LV 壁厚与年龄,血中阿尔多素和平均血压相关.
- 在APA患者中,早期的透析性LV填充 (Ei和Ei/Ai比率) 减少,心房对LV填充的贡献增加.
结论:
- 在APA患者中,过量的阿尔多与增加的LV壁厚度和质量有关.
- 与匹配的EH患者相比,APA患者表现出早期扩张性LV填充受损.
- 这些心脏变化独立于类似的血压概况和变异性而发生.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...


